PACAP immunoreactivity in human malignant tumor samples and cardiac diseases

Area of Science:

• Neuropeptide research
• Oncogenesis
• Cardiovascular pathophysiology

Background:

• Pituitary adenylate cyclase activating polypeptide (PACAP) is a multifunctional neuropeptide involved in various physiological processes.
• Recent research suggests potential clinical applications for PACAP and its analogs.
• Limited data exist on PACAP levels in human tissues affected by disease.

Purpose of the Study:

• To quantify tissue levels of PACAP38-like immunoreactivity (LI) and PACAP27-LI in non-small cell lung cancer, colon tumors, and cardiac muscle.
• To investigate PACAP levels in relation to specific cardiac conditions (ischemic heart disease vs. valvular disorders).
• To label PAC1 receptors in human cardiac cells.

Main Methods:

• Radioimmunoassay (RIA) was used to measure PACAP38-LI and PACAP27-LI in tissue samples.
• Comparison of PACAP levels between cancerous and normal tissues (lung, colon).
• Comparison of PACAP levels in cardiac muscle from patients with ischemic heart disease versus valvular disorders.

Main Results:

• PACAP38-LI was significantly higher than PACAP27-LI across all tested samples.
• Both PACAP38-LI and PACAP27-LI were significantly lower in lung and colon tumor tissues compared to normal tissues.
• PACAP38-LI and PACAP27-LI levels were significantly higher in ischemic heart disease samples than in valvular disorder samples.

Conclusions:

• PACAP levels differ significantly in cancerous tissues versus normal tissues.
• PACAP may play a role in the development or progression of oncogenesis, requiring further investigation.
• Elevated PACAP levels in ischemic heart disease suggest a potential role in this cardiovascular condition.